Glooko touted data today from a six-month pilot program that evaluated the company’s remote diabetes management technology for people with Type II diabetes.
The pilot, which spanned from April until October of 2016, involved 50 Type II diabetes patients from San Diego, Calif.-based Sharp Rees-Stealy Medical Group. The medical group evaluated patient engagement, A1c levels, LDL, microalbumin and blood pressure throughout the course of the study.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.